Cargando…

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)

Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jin Ha, Oh, Ji Young, Kim, Soo Hyun, Oh, In Jeong, Lee, Yong-ho, Lee, Keun Woo, Lee, Woong Hee, Kim, Jeong-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599508/ https://www.ncbi.nlm.nih.gov/pubmed/33050067 http://dx.doi.org/10.3390/biom10101426

Ejemplares similares

Gypenoside LXXV Promotes Cutaneous Wound Healing In Vivo by Enhancing Connective Tissue Growth Factor Levels Via the Glucocorticoid Receptor Pathway
por: Park, Sungjoo, et al.
Publicado: (2019)

Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming β-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer Property
por: Cui, Chang-Hao, et al.
Publicado: (2017)

LXXV Reunión de primavera, unión interparlamentaria = LXXV Spring conference of the inter-paliamentary union : memory : memoria.
Publicado: (1986)

Erratum in Dr Stratton's Paper in Vol. lxxv
Publicado: (1852)

Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
por: Kim, Jeong Woo, et al.
Publicado: (2020)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation
por: Li, Hongshan, et al.
Publicado: (2022)

LXXV años de evolución jurídica en el mundo.
Publicado: (1978)

LXXV años de evolución jurídica en el mundo.
Publicado: (1978)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH)
por: Yasar, Ozge, et al.
Publicado: (2022)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson’s disease treated with L-DOPA
por: Zhao, Ting Ting, et al.
Publicado: (2017)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
por: Li, Hongshan, et al.
Publicado: (2020)

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
por: Majeed, Muhammed, et al.
Publicado: (2020)

The expression and secretion of vimentin in the progression of non-alcoholic steatohepatitis
por: Lee, Su Jin, et al.
Publicado: (2014)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Gypenosides attenuate lipopolysaccharide-induced neuroinflammation and anxiety-like behaviors in rats
por: Lee, Bombi, et al.
Publicado: (2018)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
por: Connolly, James J., et al.
Publicado: (2018)

A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis
por: Kim, Jimin, et al.
Publicado: (2021)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Gypenosides Attenuate Lipopolysaccharide-Induced Neuroinflammation and Memory Impairment in Rats
por: Lee, Bombi, et al.
Publicado: (2018)

Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
por: Ji, Moongi, et al.
Publicado: (2022)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
por: Lee, Keun Woo, et al.
Publicado: (2020)

Prevalence of Non Alcoholic Steatohepatitis (NASH) and association with body mass index in obese adolescents in Padang
por: Farlina, Lita, et al.
Publicado: (2013)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0s0sce2242sn81mc7o9s2apeim